Table 1.
Cohort | No. of Tumors Total (Codon 12 / 13) |
% of Total Cohort |
Tumor, Stage |
Treatment | Findings | ||
---|---|---|---|---|---|---|---|
Multivariate HRs for KRAS mutations |
Reference Group a |
||||||
Codon 12 | Codon 13 | ||||||
Co.17, BOND, MABEL, EMR202600, EVEREST, BABEL, SALVAGE (5) |
579 (~260 / 45) | CRC IV |
BSC +/− cetuximab; Cetuximab +/− chemotherapy |
c.38G>A HR 1.82 (p =.053) for overall survival b |
BRAF/KRAS wild type or BRAF mutated |
||
OPUS, CRYSTAL (13) |
1378 (125 / 83) | 90% | CRC IV |
FOLFIRI or FOLFOX +/− cetuximab |
c.35G>T, HR 1.11 (p =.53) for overall survival c |
c.38G>A, HR 1.39 (p=.079) for overall survival c |
BRAF/KRAS wild type or BRAF mutated |
NSABP C07, C08 (9) |
2299 ( - / - ) | 48% | Colon II—III |
5FU +/− oxaliplatin, FOLFOX +/− bevacizumab |
c.35G>T, HR 1.22 (p=.16) for time to recurrence d |
BRAF/KRAS wild type or BRAF mutated |
|
PETACC-3 (18) | 1321 (368 / 102) | 40% | Colon II—III |
5FU +/− irinotecan |
c.35G>A, HR 0.98 (p =.91) c.35G>C, HR 0.97 (p =.92) c.35G>T, HR 1.09 (p =.64) c.34G>T, HR 1.40 (p =.15) c.34G>A, HR 0.99 (p =.97) for relapse-free survival d |
c.38G>A, HR 0.99 (p =.97) for relapse-free survival d |
BRAF/KRAS wild type or BRAF mutated |
CALGB 89803 (21) |
506 (123 / 53) | 40% | Colon III |
5FU +/− irinotecan |
Any Codon 12, HR 1.09 (NS) for disease-free survival d |
c.38G>A, HR 0.82 (NS) for disease-free survival d |
BRAF/KRAS wild type or BRAF mutated |
NCCTG N0147
(Alliance); Current Study |
2478 (779 / 220) BRAF wild type only |
82% | Colon III |
FOLFOX +/− cetuximab |
Any Codon 12, HR 1.52 (p <.0001) for disease- free survival d |
c.38G>A, HR 1.36 (p =.025) for disease-free survival d |
BRAF/KRAS
wild type only |
BSC, best supportive care; CRC, colorectal; HR, hazard ratio; 5FU, fluorouracil; NS, not statistically significant
Refers to the patient reference group used for prognostic analysis.
BSC-alone arm
Chemotherapy-alone arms across both trials
Data pooled across both arms